Abstracts tagged "Adverse events"

Abstract Number: 1007 • 2013 ACR/ARHP Annual Meeting
Dose Of Corticosteroid, Risk Of Adverse Events and Healthcare Resource Utilization In Systemic Lupus Erythematosus
Wei-Shi Yeh¹, Shih-Yin Chen², Kathleen McCarty³, Qian Li², Yuan-Chi Lee² and Nathalie Franchimont³, ¹Biogen Idec, Cambridge, MA, ²United BioSource Corporation, Lexington, MA, ³Biogen Idec Inc., Weston, MA
Background/Purpose: Gluco-corticosteroids (GCs) are frequently used to treat autoimmune disease and their chronic use has long been known to cause adverse events (AEs). The purpose…
Abstract Number: 742 • 2013 ACR/ARHP Annual Meeting
Safety Of Remission Induction With Rituximab Versus Cyclosphosphamide In Patients 65 and Older With Severe ANCA-Associated Vasculitis
Eli Miloslavsky¹, Ulrich Specks², Peter A Merkel³, Philip Seo⁴, Robert F. Spiera⁵, Carol A. Langford⁶, Gary S. Hoffman⁷, Cees G.M. Kallenberg⁸, E. William St. Clair⁹, Nadia Tchao¹⁰, Linna Ding¹¹, David Ikle¹², Brett Jepson¹², Paul Brunetta¹³ and John H. Stone¹⁴, ¹Division of Rheumatology, Massachusetts General Hopsital, Boston, MA, ²Mayo Clinic, Rochester, MN, ³Division of Rheumatology, University of Pennsylvania and VA Medical Center, Philadelphia, PA, ⁴Rheumatology Division, Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, ⁵Rheumatology, Hospital for Special Surgery, New York, NY, ⁶Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, ⁷Center for Vasculitis Care and Research, Cleveland Clinic Foundation, Cleveland, OH, ⁸Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ⁹Medicine, Duke University Medical Center, Durham, NC, ¹⁰Immune Tolerance Network, Bethesda, MD, ¹¹NIAID, Bethesda, MD, ¹²Rho, Chapel Hill, NC, ¹³Biotherapeutics, Genentech, So San Francisco, CA, ¹⁴Rheumatology, Massachusetts General Hospital, Boston, MA
Background/Purpose: Retrospective studies have demonstrated that patients of advanced age with systemic vasculitis experience a higher mortality and adverse events than their younger counterparts. However,…
Abstract Number: 461 • 2013 ACR/ARHP Annual Meeting
Higher TNFi Dosing Is Not Associated With More Serious Infectious Events (SIE), Elevated AST/ALT Or WBC<1.5 In The US Corrona Database
Daniel Furst¹, Mei Liu², Jeffrey D. Greenberg³ and Joel M. Kremer⁴, ¹Rheumatology, David Geffen School of Medicine, UCLA, Los Angeles, CA, ²CORRONA, Inc, Southborough, MA, ³NYU Hospital for Joint Diseases, New York, NY, ⁴Albany Medical College and The Center for Rheumatology, Albany, NY
Higher TNFi Dosing Is Not Associated with More Serious Infectious Events (SIE), elevated AST/ALT or WBC 50 mg golim. q4wk for at least 3 months.Adverse…
Abstract Number: 440 • 2013 ACR/ARHP Annual Meeting
Cardiovascular Safety Findings In Rheumatoid Arthritis Patients Treated With Tofacitinib, A Novel, Oral Janus Kinase Inhibitor
C. Charles-Schoeman¹, P Wicker², M. A. Gonzalez-Gay³, S. P. Wood⁴, M.G. Boy⁴, J. Geier⁵, D. Gruben⁴, K. Soma⁴ and R. Riese⁴, ¹Medicine-Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ²PW Consulting LLC, Mystic, CT, ³Reumatologia, Hospital Marques De Valdecilla, Santander, Spain, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc, New York, NY
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Here we evaluated the cardiovascular (CV) event rates and…
Abstract Number: 173 • 2013 ACR/ARHP Annual Meeting
HLA-DRB1*08:02 Is Associated With Bucillamine-Induced Proteinuria In Japanese Rheumatoid Arthritis Patients: A Case-Control Study
Hiroshi Furukawa¹, Shomi Oka¹, Kota Shimada², Shoji Sugii², Atsushi Hashimoto³, Akiko Komiya¹, Naoshi Fukui¹, Taiichiro Miyashita⁴, Kiyoshi Migita⁴, Akiko Suda⁵, Shouhei Nagaoka⁶, Naoyuki Tsuchiya⁷ and Shigeto Tohma¹, ¹Clinical Research Center for Allergy and Rheumatology, Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan, ²Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan, ³Department of Rheumatology, Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan, ⁴Clinical Research Center, Nagasaki Medical Center, National Hospital Organization, Omura, Japan, ⁵Center for Rheumatic Diseases, Yokohama City University Medical Center, Yokohama, Japan, ⁶Department of Rheumatology, Yokohama Minami Kyousai Hospital, Yokohama, Japan, ⁷Molecular and Genetic Epidemiology Laboratory, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan
Background/Purpose: Bucillamine (Buc) is one of the commonly used disease-modifying anti-rheumatic drugs (DMARDs) in Japan. Drug-induced proteinuria can occur in rheumatoid arthritis (RA) patients treated…
Abstract Number: 442 • 2013 ACR/ARHP Annual Meeting
Tolerability and Non-Serious Adverse Events In Rheumatoid Arthritis Patients Treated With Tofacitinib As Monotherapy Or In Combination Therapy
A. Dikranian¹, K. Soma², R. Riese², D. Gruben² and T. V. Jones³, ¹San Diego Arthritis Medical Clinic, San Diego, CA, ²Pfizer Inc, Groton, CT, ³Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is a novel, oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). Tolerability remains an ill-defined construct in clinical trials.…
Abstract Number: 2626 • 2013 ACR/ARHP Annual Meeting
Infliximab For Sight-Threatening and Refractory Uveitis Of Behcet’s Syndrome
Vedat Hamuryudan¹, Gulen Hatemi², Yilmaz Ozyazgan², Didar Ucar², Sebahattin Yurdakul², Emire Seyahi², Koray Tascilar², Serdal Ugurlu² and Hasan Yazici³, ¹Division of Rheumatology, Istanbul University, Cerrahpasa Medical Faculty, Rheumatology, Istanbul, Turkey, ²Cerrahpasa Medical Faculty University of Istanbul, Behcet's Syndrome Research Center, Cerrahpasa Medical Faculty University of Istanbul, Istanbul, Turkey, ³Cerrahpasa Medical Faculty University of Istanbul, Istanbul University, Cerrahpasa Medical Faculty, Rheumatology, Istanbul, Turkey
Background/Purpose: Uncontrolled studies suggest a beneficial effect of infliximab in the treatment of severe uveitis of BS. The majority of these studies had short observation…
Abstract Number: 459 • 2013 ACR/ARHP Annual Meeting
Transaminase Levels and Hepatic Events Observed During Tocilizumab Treatment: Pooled Analysis Of Long-Term Clinical Trial Safety Data In Patients With Rheumatoid Arthritis
MC Genovese¹, Joel M. Kremer², Ronald F. van Vollenhoven³, Rieke Alten⁴, Juan José Scali⁵, Ariella Kelman⁶, Lucy Rowell⁷ and Laura Pitts⁷, ¹Division of Immunology and Rheumatology, Stanford University Medical Center, Palo Alto, CA, ²Center for Rheumatology, Albany Medical College, Albany, NY, ³Karolinska Institute, Stockholm, Sweden, ⁴Teaching Hospital of the Charité, University of Berlin, Berlin, Germany, ⁵Durand University Hospital, Buenos Aires, Argentina, ⁶Genentech, South San Francisco, CA, ⁷Roche, Welwyn Garden City, United Kingdom
Background/Purpose: The interleukin-6 receptor inhibitor tocilizumab (TCZ) has demonstrated efficacy in improving signs/symptoms, reducing joint damage, and improving function and is well tolerated in patients…
Abstract Number: 2628 • 2013 ACR/ARHP Annual Meeting
Immunogenicity Of Infliximab Modulates Efficacy and Safety In Behcet’s Disease Patients With Uveitis
Mitsuhiro Takeno¹, Kayo Terauchi¹, Yohei Kirino^1,2, Ryusuke Yoshimi¹, Nobuhisa Mizuki², Etsuko Shibuya³ and Yoshiaki Ishigatsubo², ¹Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ²Yokohama City University Graduate School of Medicine, Yokohama, Japan, ³Department of Ophthalmology and Visual Science, Yokohama City University Graduate School of Medicine, Yokohama, Japan
Background/Purpose: Infliximab (IFX) suppresses ocular attacks in Behcet’s disease (BD) with uveitis, resulting in favorable long-term visual prognosis. However, some patients had ocular attacks which…
Abstract Number: 2640 • 2012 ACR/ARHP Annual Meeting
Methotrexate Adverse Events in a Cohort of US Veterans with Rheumatoid Arthritis
Lisa A. Davis¹, Brooke Ivan Polk², Alyse D. Mann³, Gail S. Kerr⁴, Andreas M. Reimold⁵, Grant W. Cannon⁶, Ted R. Mikuls⁷ and Liron Caplan⁸, ¹Div of Rheumatology, Univ of Colorado School of Med, Aurora, CO, ²University of Colorado Medical School, Aurora, CO, ³Research, Denver VA Medical Center, Denver, CO, ⁴Rheumatology, Washington DC VAMC, Georgetown and Howard University, Washington, DC, ⁵Rheumatology, Dallas VA and University of Texas Southwestern, Dallas, TX, ⁶Division of Rheumatology, George E. Wahlen VA Medical Center, Salt Lake City, UT, ⁷Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁸Div of Rheumatology, Denver VA and University of Colorado School of Medicine, Aurora, CO
Background/Purpose: Methotrexate (MTX) is the most commonly used medication for patients with rheumatoid arthritis (RA), however, the frequency of MTX adverse events (AE) has not…
Abstract Number: 2479 • 2012 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Does Not Increase Risk of Short Term Total Knee Replacement (TKR) Adverse Events (AE)
Zachary J. LoVerde¹, Lisa A. Mandl², Beverly K. Johnson², Mark P. Figgie³, Friedrich Boettner⁴ and Susan M. Goodman², ¹New York Medical College, Valhalla, NY, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Orthopedics, Hospital for Special Surgery, New York, NY, ⁴Orthopaedics, Hospital for Special Surgery, New York, NY
Background/Purpose: TKR is commonly performed for rheumatoid arthritis (RA) and osteoarthritis (OA). Historically, RA patients were at higher risk of post-operative AEs. The purpose of…
Abstract Number: 2483 • 2012 ACR/ARHP Annual Meeting
Folic Acid Pathway Single Neucelotide Polymorphisms Associated with Methotrexate-Related Significant Adverse Events
Lisa A. Davis¹, Brooke Ivan Polk², Alyse D. Mann³, Roger K. Wolff⁴, Gail S. Kerr⁵, Andreas M. Reimold⁶, Grant W. Cannon⁷, Ted R. Mikuls⁸ and Liron Caplan⁹, ¹Div of Rheumatology, Univ of Colorado School of Med, Aurora, CO, ²University of Colorado Medical School, Aurora, CO, ³Research, Denver VA Medical Center, Denver, CO, ⁴University of Utah, Salt Lake City, UT, ⁵Rheumatology, Washington DC VAMC, Georgetown and Howard University, Washington, DC, ⁶Rheumatology, Dallas VA and University of Texas Southwestern, Dallas, TX, ⁷Division of Rheumatology, George E. Wahlen VA Medical Center, Salt Lake City, UT, ⁸Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁹Div of Rheumatology, Denver VA and University of Colorado School of Medicine, Aurora, CO
Background/Purpose: Methotrexate (MTX) is the cornerstone medication in the treatment of rheumatoid arthritis (RA). While MTX has been associated with a number of adverse…
Abstract Number: 2169 • 2012 ACR/ARHP Annual Meeting
Short to Medium Term Safety of Glucocorticoid Therapy in Rheumatoid Arthritis: A Systematic Review and Dose-Response Analysis of Randomized Controlled Trials
Simon Tarp¹, Daniel Furst², John R. Kirwan³, Maarten Boers⁴, Henning Bliddal⁵, Thasia Woodworth⁶, Else Marie Bartels⁷, Bente Danneskiold-Samsoe⁵, Lars Erik Kristensen⁸, Steffen Thirstrup⁹, Mette Rasmussen⁹, Marian Kaldas¹⁰ and Robin Christensen¹, ¹Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark, ²Div of Rheumatology, UCLA Medical School, Los Angeles, CA, ³Academic Rheumatology Unit, Bristol Royal Infirmary, Bristol, United Kingdom, ⁴Epidemiology & Biostatistics, VU University Medical Center, Amsterdam, Netherlands, ⁵Department of Rheumatology, The Parker Institute, Copenhagen University Hospital at Frederiksberg, Copenhagen F, Denmark, ⁶Leading Edge Clinical Research LLC, Florida, FL, ⁷Department of Rheumatology, The Parker Institute, Copenhagen University Hospital at Bispebjerg and Frederiksberg, Copenhagen F, Denmark, ⁸Rheumatology, Skåen University Hospital, Lund University, Lund, Sweden, ⁹Institute for Pharmacology and Pharmacotherapy, University of Copenhagen, Copenhagen, Denmark, ¹⁰David Geffen School of Medicine, University of California in Los Angeles, Los Angeles, CA
Background/Purpose: Concerns regarding Adverse Effects (AEs) often dominate decisions on applying Glucocorticoid (GC) therapy. Evidence of AEs is mainly based on observational data without proper…
Abstract Number: 2158 • 2012 ACR/ARHP Annual Meeting
Baseline Folate Related Biomarkers in Serum and erythrocytes Are Not Associated with Methotrexate Response and Adverse Events in Rheumatoid Arthritis
Maurits C.F.J. De Rotte¹, Saskia M.F. Pluijm², Maja Bulatovic³, Johanna M.W. Hazes⁴ and Robert De Jonge¹, ¹Clinical Chemistry, Erasmus Medical Center, Rotterdam, Netherlands, ²Public Health, Erasmus Medical center, Rotterdam, Netherlands, ³Department of Paediatric Immunology, University Medical Centre Utrecht, Netherlands, ⁴Rheumatology, Erasmus MC, Rotterdam, Netherlands
Background/Purpose: Methotrexate (MTX) is the most commonly used drug in rheumatoid arthritis (RA). 30% of patients fail to respond to the drug or suffer from…
Abstract Number: 2161 • 2012 ACR/ARHP Annual Meeting
Methotrexate Polyglutamate Concentrations in Erythrocytes Are a Potential Tool for Therapeutic Drug Monitoring of Methotrexate Response in Rheumatoid Arthritis
Maurits C.F.J. De Rotte¹, Ethan den Boer², Maja Bulatovic³, Saskia M.F. Pluijm⁴, Johanna M.W. Hazes⁵ and Robert De Jonge¹, ¹Clinical Chemistry, Erasmus Medical Center, Rotterdam, Netherlands, ²Clinical Chemistry, Erasmus University Hospital, Rotterdam, Netherlands, ³Department of Paediatric Immunology, University Medical Centre Utrecht, Netherlands, ⁴Public Health, Erasmus Medical center, Rotterdam, Netherlands, ⁵Rheumatology, Erasmus MC, Rotterdam, Netherlands
Background/Purpose: Methotrexate (MTX) is the most commonly used drug in rheumatoid arthritis (RA). 30% of patients fail to respond to the drug or suffer from…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.